TIDMPYC

RNS Number : 1351V

Physiomics PLC

05 August 2020

5 August 2020

Physiomics plc

("Physiomics" or "the Company")

Issue of Equity and Director Dealing

Physiomics plc, a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, announces that following the receipt of notices of exercise of employee options, 1,655,813 ordinary shares of 0.4p each in the Company ("Ordinary Shares") (the "Options Shares") have now been issued to the following employees at the following exercise prices:

 
                     Number of Options   Exercise price 
 Grantee                 Shares issued       per option 
 Dr J Millen, CEO            1,453,923             2.5p 
                    ------------------  --------------- 
 Other staff                   201,890             2.5p 
                    ------------------  --------------- 
 

Application will be made for the Option Shares to be admitted to trading on AIM, and dealings in the Option Shares are expected to commence on 11 August 2020 ("Admission"). Following Admission, the total number of Ordinary Shares in issue will increase to 97,244,778.

For the purposes of the Financial Services Authority's Disclosure Guidance and Transparency Rules (the "DTRs"), the issued ordinary share capital of the Company following Admission will consist of 97,244,778 Ordinary Shares with voting rights attached (one vote per Ordinary Share). There are no Ordinary Shares held in treasury. This total voting rights figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interests in, or a change to their interest in, Physiomics under the DTRs. The Company's share capital additionally comprises 2,481,657,918 deferred shares of 0.036p each which are not quoted and to which no voting rights attach.

Following Admission, Dr Millen will be interested in 1,984,279 Ordinary Shares, representing approximately 2.04% of the Company's then issued share capital.

The information contained within this announcement is deemed by the Company to constitute inside information under the Market Abuse Regulation (EU) No. 596/2014.

Enquiries:

Physiomics plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

Strand Hanson Ltd (NOMAD)

Richard Tulloch & James Dance

+44 (0)20 7409 3494

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 
 1    Details of the person discharging managerial responsibilities/person closely associated 
 a)   Name                                                          James Millen 
     ------------------------------------------------------------  ---------------------------------------- 
 2    Reason for the notification 
     ------------------------------------------------------------------------------------------------------ 
 a)   Position/status                                               Director, CEO 
     ------------------------------------------------------------  ---------------------------------------- 
 b)   Initial notification/ Amendment                               Initial notification 
     ------------------------------------------------------------  ---------------------------------------- 
 3    Details of the issuer, emission allowance market participant, auction platform, auctioneer 
       or auction monitor 
     ------------------------------------------------------------------------------------------------------ 
 a)   Name                                                          Physiomics plc 
     ------------------------------------------------------------  ---------------------------------------- 
 b)   LEI                                                           213800A71DSZ6ABMTQ91 
     ------------------------------------------------------------  ---------------------------------------- 
 4    Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) 
       each type of transaction; (iii) each date; and (iv) each place where transactions have been 
       conducted 
     ------------------------------------------------------------------------------------------------------ 
 a)   Description of the financial instrument, type of instrument   Exercise of options over Ordinary share 
 
       Identification code 
                                                                     GB00BDR6W943 
     ------------------------------------------------------------  ---------------------------------------- 
 b)   Nature of the transaction                                     Exercise of options over Ordinary share 
     ------------------------------------------------------------  ---------------------------------------- 
 c)   Price(s) and volume(s)                                         Price(s)   Volume(s) 
                                                                      2.5p       1,453,923 
                                                                                ---------- 
     ------------------------------------------------------------  ---------------------------------------- 
 d)    Aggregated information 
         *    Aggregated volume                                       1,453,923 
                                                                      At 2.5p per share 
 
         *    Price 
     ------------------------------------------------------------  ---------------------------------------- 
 e)   Date of the transaction                                       5 August 2020 
     ------------------------------------------------------------  ---------------------------------------- 
 f)   Place of the transaction                                      Outside of trading venue 
     ------------------------------------------------------------  ---------------------------------------- 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCPIMFTMTTMBFM

(END) Dow Jones Newswires

August 05, 2020 02:00 ET (06:00 GMT)

Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024 Haga Click aquí para más Gráficas Physiomics.
Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024 Haga Click aquí para más Gráficas Physiomics.